ADARx Pharmaceuticals, Inc. Common Stock (ADRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ADARx Pharmaceuticals, Inc. Common Stock (ADRX) has a cash flow conversion efficiency ratio of 0.108x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-27.19 Million) by net assets ($-251.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of ADARx Pharmaceuticals, Inc. Common Stock for the company's overall valuation and market capitalisation.
ADARx Pharmaceuticals, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how ADARx Pharmaceuticals, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ADRX live share price for real-time trading data and today's change.
ADARx Pharmaceuticals, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ADARx Pharmaceuticals, Inc. Common Stock ranked by their cash flow conversion efficiency. Review ADARx Pharmaceuticals, Inc. Common Stock (ADRX) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Central China Land Media Co Ltd
SHE:000719
|
-0.033x |
|
EMEIS SA
PA:EMEIS
|
0.441x |
|
Galapagos NV ADR
NASDAQ:GLPG
|
-0.025x |
|
Zhejiang Daily Media Group Co Ltd
SHG:600633
|
0.007x |
|
Shanghai Bailian Group Co Ltd A
SHG:600827
|
0.011x |
|
Karooooo Ltd
NASDAQ:KARO
|
0.148x |
|
Sarepta Therapeutics Inc
NASDAQ:SRPT
|
-0.004x |
|
DRDGOLD Limited
JSE:DRD
|
0.251x |
Annual Cash Flow Conversion Efficiency for ADARx Pharmaceuticals, Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of ADARx Pharmaceuticals, Inc. Common Stock from 2024 to 2025. Also see ADRX asset base for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-202.25 Million | $262.29 Million | -1.297x | -466.23% |
| 2024-12-31 | $-137.15 Million | $-48.56 Million | 0.354x | -- |
About ADARx Pharmaceuticals, Inc. Common Stock
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple ind… Read more